Engineered immune cells take on tough kidney disease
NCT ID NCT07423572
First seen Feb 26, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This early-phase study tests a new treatment called UCAR-T for people with a severe kidney disease (refractory idiopathic membranous nephropathy) that hasn't responded to standard therapies. The treatment uses specially engineered immune cells to target and attack the faulty cells causing the disease. The study will enroll 18 adults to check if the therapy is safe and can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY IDIOPATHIC MEMBRANOUS NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.